Sanctura Accounts For 7.6% Of New Overactive Bladder Scripts By Urologists
Indevus/Pliva's overactive bladder product has gained 3% of new scripts overall since its August launch. Indevus plans to begin Phase III trials of Sanctura XR in mid-2005.
Indevus/Pliva's overactive bladder product has gained 3% of new scripts overall since its August launch. Indevus plans to begin Phase III trials of Sanctura XR in mid-2005.